Drug combo aims to shrink Hard-to-Treat anal cancer
NCT ID NCT07680088
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests whether the combination of pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy) can shrink tumors in people with advanced anal squamous cell cancer that cannot be removed by surgery or has spread to other organs. Participants must have already received at least one prior standard treatment. The study will measure how many patients see their tumors shrink or disappear, and how long that effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and lenvatinib
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced anal cancer that has not responded to standard therapy.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The combination may cause side effects and may not shrink tumors in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgery for Anal Cancer in HIV Patients - NCT02437851
- MR-Adaptive Radiation for Anal Cancer (NCT06050707)
- Adaptive Radiotherapy for Anal Cancer Trial NCT05838391
- HIV-Associated Anal Cancer Trial NCT04929028
- INSPIRE: Groin-Sparing Radiotherapy for Anal Can NCT05040815
- EVOLVE104 Trial for Advanced Cancers (NCT07217171)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••